MNG1144
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.592
- OXIDATIVE_PHOSPHORYLATION+0.423
- BILE_ACID_METABOLISM+0.294
- SPERMATOGENESIS+0.251
- COAGULATION+0.249
- XENOBIOTIC_METABOLISM+0.176
- ESTROGEN_RESPONSE_EARLY+0.169
- FATTY_ACID_METABOLISM+0.149
- ANGIOGENESIS+0.138
- KRAS_SIGNALING_DN+0.134
Top 10 suppressed
- MYC_TARGETS_V2-0.517
- TNFA_SIGNALING_VIA_NFKB-0.451
- G2M_CHECKPOINT-0.413
- MITOTIC_SPINDLE-0.403
- E2F_TARGETS-0.379
- TGF_BETA_SIGNALING-0.377
- INFLAMMATORY_RESPONSE-0.360
- UV_RESPONSE_DN-0.350
- WNT_BETA_CATENIN_SIGNALING-0.319
- NOTCH_SIGNALING-0.294
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0755_T1_RNA | — | B | 0.825 |
| 2 | SRR1318426 | GTEX | — | 0.806 |
| 3 | SRR1433750 | GTEX | — | 0.806 |
| 4 | BS_KZPR01BD | DNET | — | 0.802 |
| 5 | ULC0559T_S71 | — | cohortA2 | 0.795 |
| 6 | MDT-AP-2024 | Med | Medulloblastoma | 0.795 |
| 7 | SRR25617874 | — | B | 0.792 |
| 8 | MNG543 | — | — | 0.792 |
| 9 | MNG250 | — | — | 0.789 |
| 10 | MNG453 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.592 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.423 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.294 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.251 | Inavolisib | — uncovered |
| COAGULATION | 0.249 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.176 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.169 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.149 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.138 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.134 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.112 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.112 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.111 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.111 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.084 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.061 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.054 | Inavolisib | — uncovered |
| PEROXISOME | 0.023 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.011 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.008 | Inavolisib | — uncovered |